Neuromuscular Drug Development Summit

Memo

Neuromuscular diseases are a huge unmet clinical need, with huge advances and excitement in the field now is the time combine forces and help accelerate development of truly curative neuromuscular therapeutics. The inaugural Neuromuscular Drug Development Summit is industry's first dedicated discussion and networking forum focused on bringing together neuromuscular thought-leaders to share the latest scientific progress and address the current challenges drug developers are facing. With the mission to enable drug developers to solve the challenges in bringing truly transformative therapeutics to market. Join 60 of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from over 22 expert speakers on latest developments, sharing insights and science to elevate clinically effective neuromuscular therapeutic pipelines. Developed in combination with experts from Sarepta, Novartis, Sanofi and other leading organisations, this industry focused forum allows you to explore overcoming limited patient populations, innovations within gene therapy and the use of biomarkers and endpoints for increased efficacy in clinical trials to name a few. Leave NMD with a deeper understanding of the clinical, preclinical and regulatory landscape surrounding neuromuscular drug development. Download the full event guide here to view the complete agenda and companies speaking: https://goo.gl/fo7gFj URLs:Tickets: https://go.evvnt.com/244848-0?pid=5569Brochure: https://go.evvnt.com/244848-2?pid=5569  Time: 08:00 to 13:00. Venue details: The Colonnade Boston Hotel, 120 Huntington Avenue, Boston, 02116, United States. Prices:Conference + 2 Workshops Early Bird Pricing: USD 3599.0,Conference + 2 Workshops Standard Pricing: USD 3899.0. Speakers: Greg La Rosa Chief Scientific Officer, Senior Vice President, Rare Disease Research and Development Pfizer, Brian Kaspar Chief Scientific Officer Avexis, Rajeev Sivasankaran Head Rare Diseases Novartis, John Tinsley Chief Scientific Officer Summit Therapeutics, Brian Bonk Head of External Innovation and Rare Diseases Sanofi, Daniel Cohen Chief Executive Officer Pharnext, Salvador Rico Vice President, Clinical Development Audentes, Nikolai Naryshkin Executive Director PTC Therapeutics, Gregory Petsko Chief Scientific Officer MeiraGTx, Eva Chin Director Cytokinetics, Chikwendu Ibebunjo Senior Scientist Novartis, Kim Long Senior Scientist Scholar Rock, Sanjay Rakhade Senior Director, Medical Sarepta, Meg Wood Director of Development CureDuchenne, Jason Zhang Director, Biology Wave Life Sciences, Fred Cohen Chief Medical Officer Strongbridge Bio, Jinsy Andrews Director of Neuromuscular Clinical Trials Columbia University, Lale Welsh Chief Executive Officer Neuromuscular Foundation, Joanne Donavon Chief Medical Officer, Senior Vice President, Clinical Development Catabasis Pharmaceuticals, Alon Ben-Noon Chief Executive Officer NeuroSense Therapeutics, Niren Murthy Department of Bioengineering University of California, Berkley